Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

de las Heras, Begoña; Boyle, Frances; Ades, Felipe; Bozovic Spasojevic, Ivana; Capelan Rodríguez, Marta; Saini, Kamal S.; de Azambuja, Evandro

View

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months, 2020 (374.8Kb)

Author

de las Heras, Begoña

Boyle, Frances

Ades, Felipe

Bozovic Spasojevic, Ivana

Capelan Rodríguez, Marta

Saini, Kamal S.

de Azambuja, Evandro

Date

2020-12

Permanent link

https://hdl.handle.net/11351/6505

DOI

10.1007/s40487-020-00124-2

ISSN

2366-1089

WOS

000555736300001

PMID

32749634

Show full item record

Abstract

The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.

Keywords

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cancer; Immuno-oncology

Bibliographic citation

de las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, et al. Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. Oncol Ther. 2020 Dec;8:171–182.